Blog Archives

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),

Read more ›

Tags: , , , , , , , ,

Genomics lab illegally markets genetic tests that claim to predict patient responses to drugs

April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,

Read more ›

Tags: , , , , , , , ,

New treatments for multiple sclerosis and inflammatory arthritis approved

March 31, 2019 – The American Food and Drug Administration (FDA) has just approved  drugs for two rather problematic neurological conditions, namely multiple sclerosis (i.e., Cladribine (Mavenclad)) and non-radiographic axial spondyloarthritis (i.e., Certolizumab pegol (Cimzia)), offering patients with these conditions urgently need additional therapy options. FDA approves new oral treatment for multiple sclerosis

The FDA approved Cladribine (Mavenclad) tablets to treat relapsing forms of multiple sclerosis (MS ) in adults,

Read more ›

Tags: , , , , , , , ,

Unlucky women with BIA-ALCL: An update

February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,

Read more ›

Tags: , , , , , ,

Caplacizumab-yhdp (Cablivi): the first therapy for the treatment of aTTP

February 07, 2019 – The American Food and Drug Administration (FDA) just approved Caplacizumab-yhdp (Cablivi), the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),

Read more ›

Tags: , , , , , , , ,

Febuxostat (Uloric) and its problem with cardiovascular mortality

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons.

Read more ›

Tags: , , , , , , , ,

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Tagraxofusp-erzs (Elzonris) FDA approved

December 30, 2018 – Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin and often presents as or evolves into acute leukemia. The disease is more common in men than women and in patients 60 years and older.

Read more ›

Tags: , , , , , , , , ,

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

December 04, 2018 –  The American Food and Drug Administration (FDA) has just approved its first ever treatment, Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder for adult patients. LEMS affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. 

Read more ›

Tags: , , , , , ,

Living theragenomic medicine: Direct to consumer test for metabolism of drugs FDA approved

November 08, 2018 –  The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients.

Thus, FDA permits marketing, with special controls,

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Diabetes: No end to SGLT2-inhibitor drugs side effects

01 September 2018 – The American Food and Drug Administration (FDA)  is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Read more ›

Tags: , , , , , , , , , , , , , , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • When macrophages are deprived of oxygen May 24, 2019
    Infected tissue has a low concentration of oxygen. The body's standard immune mechanisms, which rely on oxygen, can then only function to a limited extent. How does the immune system nevertheless manage to control bacteria under such conditions? Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Regensburg discovered that fewer metabolites are produced in the citric […]
  • Science Snapshots -- May 2019 May 24, 2019
    Researchers at Berkeley Lab's Molecular Foundry have predicted fascinating new properties of lithium; a powerful combination of experiment and theory has revealed atomic-level details about how silver helps transform carbon dioxide gas into a reusable form; new study reports the first comprehensive, highly coordinated effort to examine the global diversity and biogeography of activated sludge […]
  • Information and language in news impact prejudice against minorities May 23, 2019
    Researchers at the Institute of Psychology show how news about immigrants and language describing immigrants shape prejudice against immigrants and other social minorities, as part of the project 'Immigrants in the Media.' For instance, nouns used for describing the ethnicity of immigrants enhance prejudice against immigrants more than adjectives.
  • Artificial atomic scale materials: Discovering how electrons fatten! May 23, 2019
    A single and isolated electron has a clear electrical charge, magnetic moment and mass, and its free movement can be precisely predicted. Spanish scientists fabricated a nanoscale artificial material manipulating atoms one after the other and discovered that electrons around are very heavier. Heavy electrons are promising particles which endow of new functionalities to novel […]
  • Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear May 23, 2019
    Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.
Top